Home LiteratureArticle Details
PMID: 16954488 Published · ppublish English Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial.

JAMA ·Vol. 296 ·No. 9 ·2006-09-06 ·Pages 1086-93

Figueiras A, Herdeiro MT, Polónia J, Gestal-Otero JJ

Abstract

Data on the adverse effects of newly marketed drugs are limited. Voluntary reporting is an important part of postmarketing surveillance but is underused by physicians. To evaluate the effectiveness of educational outreach visits for improving adverse drug reaction (ADR) reporting by physicians. A cluster-randomized controlled trial covering all National Health System physicians in the north of Portugal, with intervention in March 2004 through July 2004, and 13 to 16 months of follow-up. A total of 1388 physicians were assigned in 4 spatial clusters to the intervention group, and 5063 were assigned in 11 clusters to the control group. One-hour educational outreach visits tailored to training needs identified in a previous study. Change in total number of reported ADRs and number of serious, high-causality, unexpected, and new-drug-related ADRs, using generalized linear mixed models adjusted for baseline ADR reporting, age, specialty, and work setting. At baseline, ADR reporting rates (per 1000 physician-years) did not differ significantly between the intervention groups and the control groups in reporting ADRs overall (7.6 vs 11.3), nor did they differ significantly by category: serious, 4.3 vs 6.0; high-causality, 5.4 vs 7.6; unexpected, 1.6 vs 3.5; and new-drug-related ADRs, 3.7 vs 3.8. (P>.05 for all comparisons). The control group had no significant increase in ADR reports during follow-up. The adjusted increase in ADR reporting rates attributable to intervention was 90.19 for total ADRs (95% confidence interval [CI], 54.51-125.87; relative risk [RR], 10.23; 95% CI, 3.81-27.51), 30.16 for serious ADRs (95% CI, 18.84-41.47; RR, 6.32; 95% CI, 2.09-19.16), 64.90 for high-causality ADRs (95% CI, 38.38-91.42; RR, 8.75; 95% CI, 3.05-25.07), 28.04 for unexpected ADRs (95% CI, 16.25-39.83; RR, 30.21; 95% CI, 4.54-200.84), and 42.17 for new-drug-related ADRs (95% CI, 21.58-62.76; RR, 8.05; 95% CI, 2.10 -30.83). The greatest difference occurred during the first 4 months after intervention, but differences remained statistically significant for 12 months. A targeted outreach program may improve high-quality reporting of ADRs among physicians.

MeSH Terms
Adult Adverse Drug Reaction Reporting Systems/statistics & numerical data Cluster Analysis Education, Medical, Continuing Female Humans Male Middle Aged Physicians Portugal Practice Patterns, Physicians'/trends
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Figueiras Adolfo
Department of Preventive Medicine and Public Health, University of Santiago de Compostela, Spain, Portugal. [email protected]
Herdeiro Maria T
Polónia Jorge
Gestal-Otero Juan Jesus
Article Info
Journal
JAMA
Abbr.
JAMA
ISSN
1538-3598
Published
2006-09-06
Pages
1086-93
Language
English
Region
United States
NLM ID
7501160
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]